Angle Regulatory News (AGL)

RNS REACH

ANGLE plc

("ANGLE" or "the Company")

ANGLE LAUNCHES NEW CORPORATE WEBSITE

INCREASING FOCUS ON MEDICAL DIAGNOSTICS

ANGLE plc (AIM: AGL), the technology commercialisation company, is pleased to announce that it has launched a new corporate website, www.angleplc.com, as part of its increased focus on medical diagnostics.

ANGLE's Parsortix cell separation technology is progressing positively, and the launch of a Parsortix cancer diagnostic product for research purposes is on track for later this year. In addition, ANGLE's Novocellus subsidiary has advanced its EmbryoSureÒ IVF embryo viability product into human trials. As a result, ANGLE is re-positioning itself as a specialist medical diagnostics company.

The new ANGLE website provides more information about the Company's Parsortix cancer diagnostic device including a video introduction to the technology by Andrew Newland, ANGLE's Chief Executive.

The website also includes a video of Professor Caroline Dive, from the Paterson Institute for Cancer Research, discussing the medical significance of circulating tumour cells, which the Parsortix device is designed to capture.

Information about the Company's other key investments, Geomerics and Novocellus, and about its Management services business is also available.

The website now includes social media channels such as Twitter and an email alert service, for which shareholders are encouraged to register.

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"We are seeking to provide improved information in this new website, which includes video and other content to give a comprehensive but accessible introduction to Parsortix and its exciting development pathway."

For further information: